Astrazeneca Pharma India Ltd Sees Technical Momentum Shift Amid Mixed Signals

Technical Trend Overview and Momentum Shift

As of 2 February 2026, Astrazeneca Pharma India Ltd’s technical trend has transitioned from a clearly bearish stance to a mildly bearish one. This subtle improvement reflects a potential easing of downward pressure but does not yet indicate a definitive bullish reversal. The stock closed at ₹8,619.00, up from the previous close of ₹8,536.35, with intraday highs reaching ₹8,644.85 and lows at ₹8,431.65. Despite this intraday strength, the stock remains well below its 52-week high of ₹10,653.05, indicating room for recovery.

MACD Signals: Weekly and Monthly Perspectives

The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart, signalling that short-term momentum is still under pressure. However, the monthly MACD has improved to a mildly bearish status, suggesting that longer-term momentum is stabilising. This divergence between weekly and monthly MACD readings often points to a transitional phase where short-term volatility persists but the broader trend may be bottoming out.

RSI and Bollinger Bands: Mixed Technical Signals

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in neutral territory. This lack of directional RSI momentum implies that the stock is neither overbought nor oversold, which can precede a significant move once a directional bias emerges.

Bollinger Bands add further nuance: weekly readings are mildly bearish, indicating that price volatility remains somewhat elevated with a tendency towards downside pressure. Conversely, the monthly Bollinger Bands are bullish, reflecting a longer-term consolidation phase with potential for upward breakout if momentum improves.

Moving Averages and KST Indicator

Daily moving averages continue to signal bearishness, with the stock price trading below key averages such as the 50-day and 200-day moving averages. This suggests that short-term selling pressure remains intact. The Know Sure Thing (KST) indicator, a momentum oscillator, aligns with this view, showing bearish momentum on the weekly chart and only mildly bearish on the monthly chart. This reinforces the notion of a tentative bottoming process rather than a confirmed uptrend.

Volume and Dow Theory Analysis

On-Balance Volume (OBV) indicators show no clear trend on either weekly or monthly charts, suggesting that volume is not currently confirming price movements. This lack of volume confirmation often signals caution for traders relying on volume-based momentum.

Dow Theory readings provide a mildly bullish signal on the weekly timeframe, indicating that the stock may be forming a base for a potential upward move. However, the monthly Dow Theory shows no clear trend, reinforcing the mixed technical outlook.

Comparative Performance: Astrazeneca vs Sensex

Despite the technical uncertainties, Astrazeneca Pharma India Ltd has delivered robust returns relative to the Sensex over multiple time horizons. Over the past week, the stock gained 3.77%, outperforming the Sensex’s decline of 1.00%. Over one month, Astrazeneca’s return was -3.21%, slightly better than the Sensex’s -4.67%. Year-to-date, the stock is down 4.34%, marginally outperforming the Sensex’s 5.28% decline.

Longer-term performance is particularly impressive. Over one year, Astrazeneca returned 18.62%, significantly ahead of the Sensex’s 5.16%. Over three years, the stock surged 156.66%, dwarfing the Sensex’s 35.67% gain. Five- and ten-year returns stand at 137.31% and 598.94% respectively, compared to the Sensex’s 74.40% and 224.57%. These figures highlight Astrazeneca’s strong fundamental growth and resilience despite recent technical challenges.

Mojo Score and Rating Update

MarketsMOJO’s latest assessment downgraded Astrazeneca Pharma India Ltd from a Hold to a Sell rating on 2 January 2026, reflecting the recent technical deterioration and cautious outlook. The current Mojo Score stands at 48.0, with a Market Cap Grade of 3, indicating moderate market capitalisation but limited momentum strength. This downgrade signals that investors should exercise prudence and closely monitor technical developments before committing fresh capital.

Investor Takeaway and Outlook

In summary, Astrazeneca Pharma India Ltd’s technical parameters reveal a stock in transition. While short-term indicators such as daily moving averages and weekly MACD remain bearish, monthly indicators and Dow Theory suggest a mild improvement in momentum. The neutral RSI and mixed Bollinger Bands readings imply that the stock is consolidating and may be poised for a directional move once volume and momentum indicators align.

Investors should weigh Astrazeneca’s strong long-term performance and relative outperformance against the Sensex with the current technical caution. The downgrade to a Sell rating by MarketsMOJO underscores the need for vigilance, especially given the stock’s proximity to its 52-week low of ₹6,501.60 and the technical resistance near its recent highs.

For those considering exposure to the Pharmaceuticals & Biotechnology sector, Astrazeneca’s mixed signals suggest waiting for clearer confirmation of trend reversal before initiating new positions. Monitoring weekly MACD shifts, volume trends, and moving average crossovers will be critical in the coming weeks.

Conclusion

Astrazeneca Pharma India Ltd’s recent technical momentum shift from bearish to mildly bearish reflects a tentative stabilisation amid ongoing market volatility. While some indicators hint at potential recovery, others caution against premature optimism. The stock’s strong historical returns and relative outperformance versus the Sensex provide a solid fundamental backdrop, but the current technical landscape advises a cautious approach. Investors should continue to monitor key momentum indicators and technical signals closely to identify the optimal entry or exit points in this evolving scenario.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →